TB-500 has been the most tightly restricted peptide in the recovery category since late 2023. In July 2026, an FDA advisory committee voted in its favour for the first time. That vote changes the direction of travel. It does not change what a licensed pharmacy may legally prepare today.
This article is educational. TB-500 is a research peptide. It is not FDA-approved for any human use, and it cannot currently be compounded by a licensed US pharmacy.
The Short Answer
TB-500 sits on the FDA's Category 2 bulk drug substances list, where it was placed in late 2023. On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted favourably to recommend adding it to the 503A Bulks List.
Those two facts are not in conflict. The Category 2 listing is current law. The PCAC vote is a recommendation. Until the FDA completes formal rulemaking, TB-500 still cannot be lawfully compounded in the United States.
What the Category 2 Listing Actually Meant
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a substance without an existing USP monograph or approved drug application must be evaluated by the FDA and placed on a formal list before a compounding pharmacy may use it.
The FDA sorts nominated substances into categories while that evaluation is pending. Category 1 substances may be used at the agency's discretion while review continues. Category 2 substances are those the FDA has identified as raising significant safety risks. They are not available for compounding.
TB-500 was placed in Category 2 in late 2023. The practical effect was immediate and total: licensed compounding pharmacies could not prepare it for human use, full stop. That is why TB-500 disappeared from legitimate telehealth channels while peptides such as BPC-157 remained subjects of open regulatory discussion.
It is worth being plain about what filled that gap. Material sold online as TB-500 outside a licensed pharmacy is not a prescription product and is not subject to the sterility, potency, and identity controls that apply to compounded medications. The Category 2 listing removed the lawful route. It did not remove the demand.
Why TB-500 Drew More Scrutiny Than Its Peers
TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in actin binding, cell migration, and the formation of new blood vessels. Those are the mechanisms that generated scientific interest in it as a tissue repair candidate. Our TB-500 research overview covers that preclinical literature in more detail.
The same mechanisms are the reason regulators looked harder. Thymosin beta-4 is upregulated in several metastatic cancers, and a compound that promotes cell migration raises theoretical questions in anyone with an active or undetected malignancy. That concern has not been resolved in human studies in either direction. Combined with a thin human clinical evidence base, it gave the FDA a straightforward rationale for the more restrictive category.
This is a regulatory story, not an efficacy story. Nothing about the Category 2 listing established that TB-500 does or does not do anything in humans. It established that the agency did not consider the available safety evidence sufficient.
What Happened at the July 2026 PCAC Meeting
On 23 and 24 July 2026, the Pharmacy Compounding Advisory Committee reviewed seven peptides for possible inclusion on the 503A Bulks List.
Two things stood out.
First, the FDA's own pre-meeting briefing documents recommended against adding all seven substances. Going into the meeting, agency staff had taken a uniformly negative position.
Second, the committee did not follow that position. The panel voted favourably to recommend adding six of the seven: BPC-157, TB-500, KPV, MOTS-c, Semax, and epitalon. Only DSIP, also referred to as emideltide, was rejected.
TB-500's vote was 8 in favour, 6 against, and 1 abstention. That is the narrowest kind of endorsement, and it is worth reading it as exactly that: a divided panel disagreeing with agency staff by a margin of two votes. It is not a consensus finding of safety.
For context on how the same meeting affected a peptide with a different starting position, see our BPC-157 patient guide written ahead of the July 2026 PCAC review.
Why an Advisory Vote Is Not a Rule Change
This is the part that gets misreported, so it is worth stating carefully.
PCAC recommendations are advisory and non-binding. The committee exists to give the FDA outside expert input. The agency is not required to adopt what it hears, and it has declined committee recommendations before.
Even where the FDA agrees, a recommendation does not become a rule on its own. Adding a substance to the 503A Bulks List requires notice-and-comment rulemaking: the agency has to publish a proposed rule, open a public comment period, review the comments received, and then issue a final rule. That sequence commonly takes 12 months or more, and it can take considerably longer.
So the honest description is this: a divided advisory panel recommended a change the agency's own staff opposed, and that change would still need to survive a full rulemaking process.
Where That Leaves TB-500 Today
Nothing about availability has changed.
- TB-500 remains on the Category 2 list.
- It is not FDA-approved for any human use.
- No US licensed compounding pharmacy may lawfully prepare it for human administration.
- No telehealth service, including TelosRX, can dispense it.
If you encounter a site describing TB-500 as "approved", "now legal", or "newly available" on the strength of the July 2026 vote, that description is wrong. The vote was real. The conclusion drawn from it is not.
What Would Actually Have to Change
For TB-500 to become available through a legitimate channel, each of the following would need to happen in order:
- The FDA would have to accept the committee's recommendation rather than its own staff's position.
- The agency would have to publish a proposed rule adding TB-500 to the 503A Bulks List.
- A public comment period would have to run, and the comments would have to be reviewed.
- The FDA would have to issue a final rule.
Only after that final step could a licensed pharmacy compound it, and only then against a prescription issued by a US-licensed provider following clinical review. Provider approval is never guaranteed, and individual results vary.
How to Read Peptide Coverage in the Meantime
The gap between "recommended by an advisory committee" and "approved" is where most misleading peptide marketing now lives. Three questions separate accurate coverage from the rest.
Does it distinguish the vote from a rule? Any source that treats the July 2026 PCAC outcome as a change in legal status has skipped the entire rulemaking process.
Does it mention that FDA staff recommended against all seven? Omitting that detail makes the vote sound like an agency endorsement. It was closer to the opposite.
Does it name the vote margin? An 8 to 6 split with one abstention reads very differently from a unanimous recommendation, and sources that leave it out are usually leaving it out on purpose.
If you are comparing recovery peptides while the regulatory picture settles, our BPC-157 versus TB-500 comparison covers how the two differ in mechanism, research base, and regulatory position.
Frequently Asked Questions
Is TB-500 legal now after the July 2026 PCAC vote?
No. TB-500 remains on the FDA's Category 2 bulk drug substances list and still cannot be lawfully compounded by a licensed US pharmacy. The July 2026 committee vote was a non-binding recommendation. The FDA must complete notice-and-comment rulemaking before anything changes, and it is not obliged to proceed at all.
What was the actual TB-500 vote?
The Pharmacy Compounding Advisory Committee voted 8 in favour, 6 against, with 1 abstention, to recommend adding TB-500 to the 503A Bulks List. The committee voted favourably on six of the seven peptides reviewed: BPC-157, TB-500, KPV, MOTS-c, Semax, and epitalon. DSIP, also called emideltide, was rejected.
What does a Category 2 listing mean?
Category 2 is the FDA's designation for nominated bulk drug substances that the agency has identified as raising significant safety risks. Substances in Category 2 are not available for use by 503A compounding pharmacies. TB-500 was placed in this category in late 2023.
Did the FDA support adding these peptides?
No. The FDA's pre-meeting briefing documents recommended against adding all seven peptides under review. The advisory committee reached a different conclusion on six of them. That disagreement between agency staff and the outside panel is a meaningful part of the story.
How long could the rulemaking process take?
Notice-and-comment rulemaking commonly takes 12 months or more from proposed rule to final rule, and it can take longer. There is also no guarantee the FDA will initiate the process for TB-500, or that a final rule would include it.
Can I get TB-500 through TelosRX?
No. TB-500 cannot currently be compounded lawfully in the United States, so it is not available through TelosRX or any other legitimate telehealth service. This article is educational only and is not an offer for any product.
TB-500 is a research peptide and is not FDA-approved for any human use. It cannot currently be lawfully compounded in the United States. This article is educational, not medical advice, and is not an offer to sell or dispense any product. Where a compounded medication is available, it is not FDA-approved and is prepared under federal compounding regulations; access requires evaluation by a US-licensed provider, approval is not guaranteed, and individual results vary. TelosRX is LegitScript-certified and operates as an online-first, asynchronous telehealth service. Regulatory status described here reflects the position as of publication and may change.